A new study suggests that the earliest signs of Alzheimer’s disease may be detectable long before a person develops memory problems or dementia.
Researchers have found that certain proteins in the blood are linked to small but measurable differences in thinking abilities among healthy middle-aged adults.
The research was conducted by scientists at the University of California, San Francisco and published in The Lancet. It represents one of the strongest pieces of evidence so far that blood tests may eventually help identify Alzheimer’s disease during its earliest stages.
Alzheimer’s disease affects millions of people worldwide and is responsible for most dementia cases.
The disease gradually damages brain cells and causes worsening problems with memory, reasoning, language, and daily functioning. One of the biggest challenges facing doctors is that the disease process often begins years before symptoms become noticeable.
Scientists know that two proteins, amyloid and tau, are closely associated with Alzheimer’s disease. Amyloid forms plaques that accumulate between brain cells, while tau forms tangles inside cells. Together, these changes disrupt communication between neurons and contribute to brain cell death.
Until recently, measuring these proteins typically required specialized brain imaging or collecting spinal fluid through a lumbar puncture. Both methods can be expensive and inconvenient. Blood tests have emerged as a promising alternative because they are easier to perform and potentially more accessible to larger populations.
The UCSF researchers analyzed data from 1,350 adults aged 53 to 69 who were participating in the CARDIA study. None of the participants had dementia when the study began. Researchers measured blood levels of amyloid and tau and then assessed various aspects of cognitive function.
The results showed that around 6 percent of participants had elevated levels of both biomarkers. Although these individuals were still functioning normally in daily life, they showed subtle weaknesses on cognitive tests.
The most noticeable differences appeared in processing speed and executive function. Processing speed reflects how quickly the brain can absorb and respond to information. Executive function refers to higher-level thinking skills such as planning, organizing, decision-making, and staying focused on goals.
These abilities are essential for many everyday activities, from managing finances and keeping appointments to making decisions at work and responding to changing situations while driving.
Researchers then examined what happened over the following five years. Participants with elevated biomarker levels faced a much greater risk of rapid cognitive decline. They were approximately 2.5 to 4 times more likely to experience substantial declines in verbal memory and 3 to 4 times more likely to experience declines in processing speed.
The findings suggest that subtle difficulties in thinking speed and executive skills may be among the earliest detectable effects of Alzheimer’s-related brain changes. This challenges the common assumption that memory problems are always the first warning sign.
The study also strengthens support for blood-based testing as a future tool for identifying individuals at increased risk. Earlier detection could allow people to focus on lifestyle factors known to influence dementia risk.
These include maintaining physical activity, managing blood pressure, avoiding smoking, treating depression, staying mentally engaged, and supporting overall cardiovascular health.
According to the researchers, up to 40 percent of dementia cases may be delayed or prevented by addressing modifiable risk factors. If people can be identified earlier, they may have more time to adopt healthy habits that could help protect brain function.
At the same time, experts caution that blood tests are not yet a perfect solution. The tests can produce false positive results, and they only identify Alzheimer’s-related biological changes rather than other forms of dementia. For this reason, researchers emphasize that blood tests should be interpreted carefully and used alongside other clinical information.
The study’s large sample size and diverse participant population strengthen confidence in the findings. However, further studies will be needed to determine whether routine testing of healthy adults is beneficial and whether interventions based on biomarker results can significantly alter disease progression.
In reviewing the evidence, the study provides an important step forward in Alzheimer’s research. It shows that biological signs of the disease can be detected in some healthy adults years before dementia develops and that these signs are linked to measurable cognitive changes.
While many questions remain unanswered, the findings support the growing hope that earlier detection could eventually lead to more effective prevention and treatment strategies.
